SAGE Therapeutics (SAGE) Misses Q2 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. SPCX
9. WDC
10. QGEN

Go back to SAGE Therapeutics (SAGE) Misses Q2 EPS by 13c

Oppenheimer Reiterates Perform Rating on Sage Therapeutics (SAGE)

August 7, 2023 4:56 PM EDT

Oppenheimer analyst Jay Olson reiterated a Perform rating and $20.00 price target on Sage Therapeutics (NASDAQ: SAGE)

The analyst comments "SAGE is focused on delivering newly-approved Zurzuvae to PPD patients while accelerating development of pipeline assets and rationalizing OpEx spending. We... More

SAGE Therapeutics (SAGE) sinks nearly 50% as trading resumes following CRL

August 7, 2023 7:12 AM EDT

SAGE Therapeutics (NASDAQ: SAGE) sinks 47% as trading resumes after FDA approval for ZURZUVAETM in postpartum depression (PPD) but a CRL for major depressive disorder (MDD).

... More